Key clinical point: Molecular clearance of psoriasis at the gene expression level is the new frontier.
Major finding: The likelihood of experiencing residual psoriasis signs and symptoms, even after achieving a PASI 100 response, appears to depend upon the mechanism of action of the medication used to clear the skin.
Study details: This was a secondary analysis of the randomized, head-to-head VOYAGE 1 and 2 trials of guselkumab versus adalimumab for psoriasis.
Disclosures: The presenter serves as a scientific advisor to and paid clinical investigator for Janssen, which sponsored the study, as well as for roughly two dozen other pharmaceutical companies.
Blauvelt A. AAD 2020 LBCT.